Edition:
India

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

52.71USD
18 May 2018
Change (% chg)

$-0.03 (-0.06%)
Prev Close
$52.74
Open
$52.88
Day's High
$53.14
Day's Low
$52.43
Volume
1,887,099
Avg. Vol
2,105,003
52-wk High
$70.04
52-wk Low
$49.97

Chart for

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $106,283.60
Shares Outstanding(Mil.): 1,639.93
Dividend: 0.39
Yield (%): 2.41

Financials

  BMY.N Industry Sector
P/E (TTM): 23.62 30.95 32.75
EPS (TTM): 2.74 -- --
ROI: 18.60 14.84 14.38
ROE: 30.97 16.34 16.07

Setback to Roche hopes for Tecentriq as fails key cancer trial

ZURICH Roche's hopes of its Tecentriq immunotherapy catching rival medicines from Merck and Bristol-Myers Squibb were dealt a blow on Thursday after it failed a key combination trial.

10 May 2018

Roche's Tecentriq combo wins fast FDA review in race to catch rivals

ZURICH Roche's immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get an accelerated review by U.S. regulators for use as an initial treatment of a common form of lung cancer, the Swiss drugmaker said on Monday.

07 May 2018

UPDATE 1-Roche's Tecentriq combo wins fast FDA review in race to catch rivals

ZURICH, May 7 Roche's immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get an accelerated review by U.S. regulators for use as an initial treatment of a common form of lung cancer, the Swiss drugmaker said on Monday.

07 May 2018

BRIEF-Bristol-Myers Squibb Elects Each Of Company's 12 Nominees To Serve As Directors

* BRISTOL-MYERS SQUIBB CO - SHAREHOLDERS ELECTED EACH OF COMPANY'S 12 NOMINEES TO SERVE AS DIRECTORS OF COMPANY UNTIL 2019 ANNUAL MEETING

04 May 2018

BRIEF-EMA Validates Bristol-Myers' Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment Of First-Line Metastatic Non-Small Cell Lung Cancer

* EUROPEAN MEDICINES AGENCY VALIDATES BRISTOL-MYERS SQUIBB'S TYPE II VARIATION APPLICATION FOR OPDIVO PLUS YERVOY COMBINATION FOR TREATMENT OF FIRST-LINE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

03 May 2018

BRIEF-Bristol-Myers Squibb And Flatiron Health Expand Collaboration With A Three-Year Agreement

* BRISTOL-MYERS SQUIBB AND FLATIRON HEALTH EXPAND COLLABORATION WITH A THREE-YEAR AGREEMENT

02 May 2018

UPDATE 3-Keytruda sales power Merck to quarterly beat

* Shares drop 2.8 pct (updates share price, adds analyst and CEO quote)

01 May 2018

BRIEF-Advantagene Announces Clinical Trial Collaboration

* ADVANTAGENE INC SAYS COMPANY ENTERED INTO A CLINICAL TRIAL COLLABORATION WITH BRISTOL-MYERS SQUIBB

27 Apr 2018

UPDATE 3-Bristol-Myers raises 2018 forecast, some sales disappoint

NEW YORK, April 26 Bristol-Myers Squibb Co on Thursday significantly raised its full-year earnings forecast even as first-quarter sales of some medicines fell short of expectations and sent shares of the U.S. drugmaker down almost 1 percent.

26 Apr 2018

BRIEF-CEO Says Bristol-Myers Still A Growth Company

* BRISTOL-MYERS SQUIBB SEES CONTINUED GROWTH IN ANTICOAGULANT MARKET SHARE FOR ELIQUIS

26 Apr 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $124.24 +0.39
Pfizer Inc. (PFE.N) $35.64 -0.07
Merck & Co., Inc. (MRK.N) $59.14 +0.07
Sanofi SA (SASY.PA) €66.44 +0.32
AstraZeneca plc (AZN.L) 5,241.00 -104.00
GlaxoSmithKline plc (GSK.L) 1,488.20 -2.20
Eli Lilly And Co (LLY.N) $82.07 +0.41
Roche Holding Ltd. (ROG.S) CHF224.55 +0.55
Roche Holding Ltd. (RO.S) CHF229.20 +1.00

Earnings vs. Estimates